NEW YORK (GenomeWeb) – Medicare contractor Noridian has issued a final local coverage decision (LCD) for Myriad Genetics' Prolaris, a test for gauging prostate cancer aggressiveness.

In January this year, another Medicare contractor, Palmetto GBA, issued a final LCD on the same test when used for low- and very low-risk prostate cancer patients. Similarly, the final LCD from Noridian, which goes into effect on October 15, will cover testing for prostate cancer patients defined as low and very low risk by the National Comprehensive Cancer Network. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a commentary at eLife, Brandeis University's Eve Marder calls on researchers to value and pursue truth.

Researchers have developed a way to quickly edit white blood cells, according to the New York Times.

In Science this week: rice gene enables plants to grow quickly in times of flooding, and more.

Education-linked genetic variants could also predict a small portion of a person's social mobility, Newsweek reports.